“What we really don’t control and don’t attempt to but as a reality is that downstream customers from Lilly wholesalers and retailers are making their own decisions about which of the 12 ...

CEO David Ricks admitted on CNBC that the underperformance was due to an oversupply of the drugs, emphasizing that Lilly hadn't commenced advertising Zepbound as planned. The focus remained on ramping ...

By destocking, he’s referring to the idea that wholesalers were selling existing inventory in the third quarter rather than buying and selling even more of the company’s drugs. Lilly competes ...

The company said third-quarter sales of the drugs were negatively impacted by inventory decreases among wholesalers. Supply increases allowed Eli Lilly to fulfill back orders for wholesalers in ...

During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro. Wholesalers purchase medicines from manufacturers and sell them to ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...